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The human USP7 deubiquitinating enzyme was
shown to regulate many proteins involved in the
cell cycle, as well as tumor suppressors and onco-
genes. Thus, USP7 offers a promising, strategic tar-
get for cancer therapy. Using biochemical assays
and activity-based protein profiling in living systems,
we identified small-molecule antagonists of USP7
and demonstrated USP7 inhibitor occupancy and
selectivity in cancer cell lines. These compounds
bind USP7 in the active site through a covalentmech-
anism. In cancer cells, these active-site-targeting
inhibitors were shown to regulate the level of several
USP7 substrates and thus recapitulated the USP7
knockdown phenotype that leads to G1 arrest in
colon cancer cells. The data presented in this report
provide proof of principle that USP7 inhibitors may
be a valuable therapeutic for cancer. In addition,
the discovery of such molecules offers interesting
tools for studying deubiquitination.INTRODUCTION
Deregulation of the ubiquitin-proteasome system has been
implicated in the pathogenesis of many human diseases,
including cancer. The effectiveness of the proteasome inhibitor
Velcade (bortezomib) in the treatment of multiple myeloma and
mantle cell lymphoma establishes the ubiquitin-proteasome
system as a valid anti-cancer therapeutic target (Cohen and
Tcherpakov, 2010). Mono- and polyubiquitination can be
reversed by deubiquitinating enzymes (DUBs), which specifically
cleave the isopeptide bond at the C terminus of ubiquitin
(Komander et al., 2009; Nijman et al., 2005). USP proteins consti-
tute the largest subfamily of DUBs, with more than 60 human
members. These enzymes remove ubiquitin from specific protein
substrates, making it possible to retrieve these proteins from
proteasomal degradation and alter their location and activation
(Komander et al., 2009; Nijman et al., 2005). Based on their
protease activity and involvement in several human diseases,Chemistry & Biology 19,USPs are emerging as potential targets for pharmacological
disruption of the ubiquitin regulation machinery (Colland, 2010;
Drag and Salvesen, 2010).
USP7/HAUSP (herpes virus-associated USP) is a 135 kDa
protein in the USP family of DUB enzymes. In addition to a
DUB domain, USP7 also contains an N-terminal TRAF-like
MATH domain (Zapata et al., 2001) and a C-terminal domain
that contains at least five ubiquitin-like domains (Faesen et al.,
2011). This protein is produced ubiquitously and is highly con-
served in eukaryotes. USP7 is primarily a nuclear protein and
localizes to a subset of PML bodies (Everett et al., 1999;Muratani
et al., 2002). At the molecular level, by virtue of its deubiquitinat-
ing activity, USP7 has been shown to regulate the steady-state
level of several poly-ubiquitinated substrates. For example,
USP7 alters the level of the p53 and p16INK4a tumor suppressors
through Mdm2 stabilization and Bmi1/Mel18 stabilization,
respectively (Cummins et al., 2004; Li et al., 2004; Maertens
et al., 2010). USP7 binding to p53 was recently shown to be
regulated by TSPYL5, a protein potentially involved in breast
oncogenesis through its competition with p53 for binding to
the same region of USP7 (Epping et al., 2011). Additional
proteins involved in genomic integrity and regulation, such as
the DNMT1 DNA methylase and the claspin adaptor, are also
stabilized by USP7 (Du et al., 2010; Faustrup et al., 2009).
Interestingly, USP7 was shown to regulate the cellular compart-
mentalization of several mono-ubiquitinated substrates by
deubiquitination. In this respect, the PTEN and FOXO4 tumor
suppressors are inactivated by USP7-induced nuclear export
(Song et al., 2008; van der Horst et al., 2006). USP7 overexpres-
sion was also reported in human prostate cancer and was
directly associated with tumor aggressiveness (Song et al.,
2008). Previous in vivo data also underlined the involvement of
USP7 in cancer cell proliferation (Becker et al., 2008). Altogether,
the phenotypes associated with USP7-silencing, as well as the
connections between USP7 and several pathways involving
oncogenes and tumor suppressors, strongly suggest that target-
ing USP7 by small-molecule inhibitors may be of therapeutic
value in cancer treatment.
We developed advanced high-throughput screening-compat-
ible assays using optimized USP substrates, including various
ubiquitin derivatives and specific physiological substrates, to
screen a chemically diverse library of small molecules. From a
pioneering program, HBX 41,108 was found to inhibit USP7467–477, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 467
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Figure 1. Identification of HBX 19,818 and HBX 28,258 as USP7 Inhibitors
(A) Structures of the amidotetrahydroacridine derivatives HBX 19,818, HBX 28,258, and HBX 28,364.
(B) Dose-dependent inhibition of USP7 activity by HBX 19,818 and HBX 28,258 using the Ub-AMC substrate. The results are shown as means ± SD of triplicate
values and are representative of four independent experiments.
(C) Dose-dependent inhibition of USP7 activity by HBX 19,818 and HBX 28,258 using the Ub-52 substrate. The results are shown as means ± SD of triplicate
values and are representative of four independent experiments.
(D) HBX 19,818 and HBX 28,258 inhibit USP7 deubiquitination of polyubiquitinated p53. The purified wild-type or mutant (C223A) USP7 enzyme (3 nM final
concentration) was incubated with HBX 19,818 (1.5, 4, 12, 36, or 100 mM), HBX 28,258 (4, 12, 36, or 100 mM), or HBX 28,364 (100 mM) for 1 hr at room temperature
before the addition of purified polyubiquitinated p53 and incubation for 1 hr at 37C. The results are representative of two independent experiments.
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USP7-mediated p53 deubiquitination in vitro and in cells. Like
RNAi-mediated USP7 silencing in cancer cells, HBX 41,108
treatment stabilized p53, activated the transcription of a p53
target gene, and inhibited cancer cell growth (Colland et al.,
2009). One of the main problems hindering the development of
small-molecule inhibitors of cysteine proteases has been their
lack of specificity (Altun et al., 2011). Work carried out over
the last few years has led to the identification of inhibitors with
selective action against various DUB targets demonstrating the
feasibility of selectively targeting deubiquitinating enzymes.
The PLPro-specific inhibitors (Ratia et al., 2008), the USP14-
specific inhibitors (Lee et al., 2010), and the USP1-specific inhib-
itors (Chen et al., 2011) are three such examples. We describe
here the identification of selective small-molecule antagonists
of USP7 that bind in its active site through a covalent mecha-
nism. In cellular models, these active-site targeting inhibitors
were shown to bind directly and specifically to USP7 and modu-
late the steady-state levels of several USP7 substrates.
RESULTS
Identification of USP7-Small Molecule Inhibitors
To identify USP7 inhibitors, we performed an in vitro high-
throughput screen (HTS) against a diverse library of synthetic
chemicals using ubiquitin C-terminal 7-amido-4-methylcou-468 Chemistry & Biology 19, 467–477, April 20, 2012 ª2012 Elseviermarin (Ub-AMC) as a substrate (Dang et al., 1998). Full-length
USP7 protein was produced as a functional enzyme in baculovi-
rus-infected insect cells and purified using a His-tag fusion
method as previously described (Colland et al., 2009). The Z
and Z’ factors, which are standard statistical parameters for
HTS assays, were 0.76 and 0.92, respectively, confirming HTS
assay robustness (Zhang et al., 1999). From this screening, we
discovered a structural class of small molecules represented
by HBX 19,818 and HBX 28,258 (Figure 1A). These compounds
inhibited USP7 activity with IC50 of 28.1 and 22.6 mM, respec-
tively (Figure 1B). We obtained similar IC50 for these compounds
using an assay based on another substrate, the natural ubiquitin
precursor Ub52, which confirmed the efficacy of each com-
pound (Figure 1C). We sought to confirm this finding using a
more physiological USP7 substrate, polyubiquitinated p53
(polyUb-p53), which we generated in vitro using the ubiquitin
ligase Mdm2 as previously described (Colland et al., 2009).
Wild-type USP7—but not the catalytically inactive C223A
mutant—deubiquitinated the polyUb-p53 substrate (Figure 1D).
We then assessed the effects of HBX 19,818 and HBX 28,258
on USP7-mediated p53 deubiquitination and showed that both
molecules exhibited a dose-dependent effect on USP7 activity
(Figures 1A and 1D). In contrast, a related inactive compound,
HBX 28,364, devoid of the basic alkyl amine side chain, did not
exhibit any inhibitory activity (Figures 1A and 1D). This new
structural class of small molecules is thus able to inhibitLtd All rights reserved
AB C
Figure 2. HBX 19,818 and HBX 28,258 Selectively Inhibit USP7
(A) A panel of ten representative active cysteine proteases was established to evaluate the specificity of HBX 19,818 and HBX 28,258 in vitro.
(B) This panel shows a gel from a HAUbVS competition assay for HBX 19,818 (3, 6, 12.5, 25, 50, and 100 mM), NEM (5 mM), and HBX 41,108 (50 mM) with the
HCT116 proteome. All active DUBs were identified using anti-HA antibody. Note that HBX 19,818 blocks only USP7 and not the other deubiquitinating enzymes.
(C) HAUbVS competition assay gels comparing the activity of HBX 19,818, HBX 28,364, and HBX 41,108 inhibitors against USP7 and additional deubiquitinating
enzymes (USP8, USP5, USP10, CYLD, and UCH-L3) in native HCT116 cell lysate. HBX 19,818 exhibits specific and concentration-dependent inhibition of USP7
labeling by HAUbVS in the HCT116 proteome.
See also Figures S1 and S2.
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logically relevant, substrates.
Selectivity of the Small-Molecule Inhibitors of USP7
We evaluated the specificity of HBX 19,818 and HBX 28,258 for
USP7 relative to other proteases by assessing the inhibitory
effects of these compounds in vitro against a representative
set of recombinant proteases. Interestingly, neither compound
exhibited any cross-reactivity on other USP members, such as
USP8, USP5, USP2, and USP20 (IC50 > 200 mM; Figure 2A).
We also assessed the specificity of HBX 19,818 and HBX
28,258 for USP7 by assessing their activities on two related
deubiquitinating enzymes, UCH-L1 and UCH-L3 (ubiquitin
C-terminal hydrolase-L1 and L3), and on SENP1, a SUMO
protease. Both compounds were inactive against these ubiquitin
and ubiquitin-like proteases (IC50 > 200 mM). As USP7 is a thiol
protease, we also investigated the effects of these inhibitors onChemistry & Biology 19,other proteases from this family. Neither compound had any
significant activity against cathepsin B and caspase-3 (Fig-
ure 2A). Evaluation of HBX 19,818 and HBX 28,258 at inhibitor
concentrations up to 1 mM confirmed these findings (Figure S1
available online), thus showing that inhibition of these com-
pounds is at least 30-fold more stronger with USP7 than with
the other enzymes tested.
To confirm the specificity observed in vitro using recombinant
enzymes, we performed competition assays using the HAUbVS
activity-based probe (ABP), which binds covalently to the
cysteine active site of deubiquitinating enzymes (Borodovsky
et al., 2002; Hemelaar et al., 2004; Ovaa et al., 2004). Compared
to in vitro assays of individual recombinant enzyme activity, the
HAUbVS assay has the advantage of being able to evaluate
the effects of inhibitors against numerous deubiquitinating
enzymes in native proteomes directly and in parallel, through
western blotting with anti-HA antibody. In this assay, an inhibitor467–477, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 469
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is determined by labeling the residual active deubiquitinating
enzymes with the HAUbVS. When lysed HCT116 cells were
treated with HAUbVS in the absence and presence of the
nonspecific DUB inhibitor HBX 41,108 (Figures 2B, S2A, and
S2B), a strong reduction of the labeling of most active DUBs
was observed. Interestingly, in the presence of HBX 19,818,
the immunoblot pattern remained largely unchanged with the
exception of one band, at the size corresponding to HA-Ub-
VS-USP7, which was almost completely eliminated at the higher
doses of HBX 19,818 (Figure 2B). This effect of HBX 19,818 on
USP7 activity was confirmed using an anti-USP7 antibody as
indicated by the mobility shift observed between the treated
and nontreated samples (Figures 2B and 2C). We confirmed
these findings by testing the activity of HBX 19,818 in a different
proteome and by testing the second compound, HBX 28,258
(Figures S2A and S2C).
We next evaluated the effect of USP7 inhibitors on HAUbVS
labeling efficiency by monitoring several deubiquitinating
enzymes individually. To this end, we used specific antibodies
to assess the labeling efficiency of HAUbVS for USP7, USP8,
USP5, USP10, CYLD, and UCH-L3 from HCT116 cell lysates.
Labeling was confirmed with all tested DUBs, as indicated by
the mobility shifts observed between the HAUbVS-treated and
nontreated samples albeit with different levels of efficiency (Fig-
ure 2C, lanes 1 and 2). We then evaluated HBX 19,818, the
nonspecific DUB inhibitor HBX 41,108, and the inactive
compound HBX 28,364 for their ability to inhibit the labeling of
these DUBs by HAUbVS. As expected, we found that HBX
41,108 inhibited the labeling of all DUBs tested, whereas HBX
28,364 did not exhibit any inhibitory activity (Figure 2C). In
contrast, HBX 19,818 efficiently blocked labeling of USP7 but
not that of USP8, USP5, USP10, CYLD, or UCH-L3, showing
this compound’s specificity for USP7 over a panel of active
DUBs under physiological conditions (Figure 2C). Taken
together, these results indicate that HBX 19,818 and HBX
28,258 are selective inhibitors of the human USP7 enzyme.
Mode of Action of USP7-Selective Small Molecule
Inhibitors
Complexes involving USP7 and HBX 19,818 were characterized
by electrospray ionization mass spectrometry (ESI-MS) under
nondenaturing conditions. Increasing concentrations of HBX
19,818 (one to ten molar equivalents) were incubated with
purified USP7(K208-E560), and complex formation was
subsequently monitored by native MS. HBX 19,818 was shown
to form stoichiometric complex with USP7, which proportion
gradually increased with compound concentration, reaching
about 80% in the presence of ten molar equivalents (Figure 3A).
Only a 1:1 protein/ligand complex was detected in spite of large
excess of compound, emphasizing HBX 19,818 binding
specificity.
Interestingly, mass shift between unbound and bound USP7
revealed a difference of about 36 Da compared to HBX
19,818 molecular weight (MW; measured mass shift: 386 Da
vs. HBX 19,818 average MW: 422 Da), suggesting that part of
the molecule and/or the protein is lost upon binding. Moreover,
whereas protein/ligand complexes can be usually dissociated
using collision-induced dissociation experiments (for review,470 Chemistry & Biology 19, 467–477, April 20, 2012 ª2012 Elseviersee Vivat Hannah et al., 2010), USP7/HBX 19,818 complex
turned out to be extremely stable in the gas phase (data not
shown), raising the hypothesis of a covalent interaction
between USP7 and HBX 19,818. This observation was in agree-
ment with dose response of USP7 inhibition showing time-
dependent decrease of IC50 values as expected for an irrevers-
ible inhibitor (Figure 3B). Covalent bonding of HBX 19,818 to
USP7 was finally confirmed by MS analysis under denaturing
conditions, revealing that USP7/HBX 19,818 complex remains
intact after dilution in 50% acetonitrile acidified with 0.5% for-
mic acid (Figure S3A). To gain deeper insights into HBX
19,818 covalent bonding to USP7, reverse-phase liquid chro-
matography (RPLC) followed by UV and MS detection was
used to analyze peptides resulting from trypsin-digested
USP7/HBX 19,818 complex (Figure S3B). Comparison of UV
chromatogram monitored at l = 214 nm (absorbance maximum
of peptide bond) and l = 332 nm (absorbance maximum of HBX
19,818) revealed two peaks at RT = 44.5 min and RT = 73.1 min
absorbing at l = 332 nm, which suggests that these peptides
carry covalently bound HBX 19,818. Tryptic peptides were
then assigned based on their measured MW, which gave rise
to 86% sequence coverage, including six out of the seven
cysteines (Figure S3C).
To precisely localize the HBX 19,818 binding site in USP7,
ligand-bound peptides were submitted to MS/MS experiments.
In the case of peptide 218-239, MS/MS spectrum (Figure 3C)
displayed numerous fragments providing almost complete
sequence coverage. The residue involved in HBX 19,818 cova-
lent bonding was assigned to Cys223; this was evidenced by
the 488.2 Da difference between fragments b5 and b6, whereas
a 103.0 or 160.0 Da shift would have been expected for a free or
alkylated cysteine, respectively. Similarly, for ligand-bound
peptide 313-322, MS/MS spectrum revealed that HBX 19,818
is attached to Cys315 (Figure S4A). Based on UV chromatogram
(l = 332 nm) peak areas (Figure S3B), the abundance ratio of
HBX 19,818-bound peptides 218-239 and 313-322 was esti-
mated to 95/5. This result underpins HBX 19,818 selectivity
toward Cys223, knowing also that two out of the six other cyste-
ines present in USP7 have side-chain solvent-accessible surface
areas 4–5 times higher than Cys223 (Figure S3D). Considering
HBX 19,818 molecular formula (Figure 1A), the observed mass
increase of 385.2 Da rather than the expected 421.2 Da shift
expected from HBX 19,818 monoisotopic mass is explained by
HCl release upon covalent bonding (HCl monoisotopic mass:
36.0 Da), as confirmed by high-resolution MS experiments
(Figure S4B).
Altogether, combining several MS approaches demonstrated
that HBX 19,818 selectively forms a covalent bond with the
Cys223 located in the USP7 active site.
To further understand the structural basis of the binding of
HBX19,818 to USP7, we carried out molecular docking studies.
USP7 has been crystallized in apo-form and together with cova-
lently bound ubiquitin aldehyde (Hu et al., 2002). The observa-
tions of the X-ray structures indicate that the active site of the
free USP7 core domain exists in an unproductive conformation
and that substrate binding will likely trigger a conformational
change (catalytic triad in close proximity) that results in catalysis.
The docking results show that HBX 19,818 is able to interact with
the substrate (ubiquitin) binding pocket of USP7 (Figure S5A). ItLtd All rights reserved
Figure 3. Mode of Action of USP7-Selective Small Molecule Inhibitors
(A) Native MS analysis of USP7 incubated at 5 mM in 10 mMNH4Ac (pH 7.5) for 15 hr at 18
C either alone (upper mass spectrum) or in the presence of 50 mMHBX
19,818 (lower mass spectrum).
(B) Time-dependent inhibition of USP7 by HBX 19,818. USP7 (100 pM) was pre-incubated for different time points (from 30min to 6 hr) with DMSO or HBX 19,818
(25 mM) before initiating the enzymatic reaction by adding UbAMC substrate (300 nM).
(C) MS/MS analysis of HBX 19,818-bound peptide 218-239 eluting at 73.6 min in Figure S3B (lower chromatogram).
See also Figures S3, S4, and S5.
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active site Cys223, which enables the formation of a covalent
bond between the sulfur atom of Cys223 and the carbon atom
bearing the chloro group. This reaction results in the loss of
HCl as previously shown in the mass spectrometry study.
Further interactions that are observed are strong electrostatic
interactions between the basic amino group and two acidic
residues (Asp295 and Glu298) located at the entrance of the
ubiquitin binding pocket. However, further experimental data,
such as crystal structures, are necessary to confirm this docking
hypothesis.Chemistry & Biology 19,HBX 19,818 Selectively Inactivates USP7 in Living Cells
Having demonstrated that HBX 19,818 binds selectively to the
active site of USP7 in vitro, we next asked whether HBX 19,818
could inhibit the labeling of USP7 by HAUbVS in living HCT116
cells treated with various amounts of this inhibitor. HBX 19,818
proved to be active in cells, as it almost completely inhibited
USP7 labeling at 25 mM (Figure 4A). At this concentration, we
also found that HBX 19,818 did not block the labeling of
several other DUBs, such as USP8, USP5, USP10, CYLD, or
UCH-L3 (Figure 4A). These data clearly demonstrate that
HBX 19,818 targets USP7 directly in cells and does not467–477, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 471
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Figure 4. HBX 19,818 Selectively Inhibits USP7 in Human Cancer Cells
(A) Living HCT116 cells treated with HBX 19,818 (1.5, 3, 6, 12, or 25 mM) for 6 hr were then labeled with the HAUbVS probe (1 mM, 15 min). Among the six
deubiquitinating enzymes detected by HAUbVS, only USP7 labeling was inhibited by HBX 19,818 (IC50 6 mM). Individual DUBs were identified using specific
antibodies.
(B) Ubiquitinated proteins from HEK293 cells that had been transfected with constructs encoding Mdm2, USP7 (wild-type or inactive C223A mutant), and
His-tagged ubiquitin and had been treated with HBX 19,818 (5, 10, or 25 mM) were precipitated using Ni-NTA agarose (PD, pull-down). Western blots were
analyzed for the presence of Mdm2 and USP7.
(C) The half-life of endogenous Mdm2 and p53 was monitored in SJSA-1 osteosarcoma cells treated with cycloheximide for different times (0, 0.5, 1, 2, or4 hr)
in the presence of HBX 19,818 (30 mM) for 24 hr. Western blots were analyzed for the presence of Mdm2, p53, and actin.
(D) Endogenous levels of Mdm2, p53, and p21 were monitored in HCT116 colon cancer cells treated with HBX 19,818 or HBX 28,258 (6–20 mM) for 24 hr.
(E) Endogenous levels of claspin, Chk1, Chk1-pS317, and p53 were monitored in U2OS osteosarcoma cells. Cells were treated with HBX 19,818 (5–20 mM) for
24 hr then subsequently treated with UV (10 mJ/cm2) and harvested 1 hr later. Cells were then processed for immunoblotting.
See also Figure S6.
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tested.
USP7 stabilizes the product of the well-characterized onco-
gene, mdm2, through specific deubiquitination (Cummins
et al., 2004; Li et al., 2004). To confirm that HBX 19,818 inhibits
USP7 activity in cells, we developed an assay tomonitor the level
of the ubiquitinated form of Mdm2 in HEK293 cells. To this end,
His-tagged ubiquitin, Mdm2, and USP7 were produced together
in HEK293 cells. Ubiquitinated proteins were then pulled down
and the polyubiquitinated forms of Mdm2 were detected by
immunoblotting with an anti-Mdm2 antibody. In this context,472 Chemistry & Biology 19, 467–477, April 20, 2012 ª2012 Elsevierthe levels of polyubiquitinated Mdm2 proteins were far lower in
the presence of wild-type USP7 than in the presence of the
catalytically inactive form of USP7 (Figure 4B, compare lanes 2
and 6), which is consistent with previous reports (Cummins
et al., 2004; Li et al., 2004). This assay was used to investigate
the effect of HBX 19,818 on USP7-mediated Mdm2 deubiquiti-
nation. Incubation of USP7-overproducing HEK293 cells with
various amounts of HBX 19,818 for 24 hr resulted in significantly
higher levels of Mdm2 polyubiquitinated forms than those in
DMSO-treated control cells (Figure 4B, compare lanes 2 and
5). Thus, HBX 19,818 partially reverses the deubiquitination ofLtd All rights reserved
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inhibits a biological activity of USP7 in living cells. We also moni-
tored the level of endogenous Mdm2 in cancer cell lines, such as
SJSA-1 osteosarcoma cells that contain an amplified mdm2
oncogene. In these cancer cells, HBX 19,818 treatment caused
a sharp reduction in the steady-state level of endogenous
Mdm2, which was accompanied by a strong induction of
p53 (Figure 4C, see also Figure S6A for quantification). Incuba-
tion of exponentially growing HCT116 cells with HBX 19,818
and HBX 28,258 for 24 hr also led to an increase in the levels
of p53 and of the products of its target genes, such as the
cyclin-dependent kinase inhibitor p21cip1/waf (Figure 4D, see
also Figure S6B for quantification). This result indicated that
HBX 19,818 induces the functional activation of p53 in mamma-
lian cells.
Claspin and USP7 interact in vivo, and USP7 is a regulator of
claspin stability (Faustrup et al., 2009). As USP7-silencing results
in claspin degradation in U2OS osteosarcoma cells, we evalu-
ated whether HBX 19,818 treatment affected the endogenous
levels of claspin in these cells. Cells treated for 24 hr exhibited
dose-dependent claspin degradation (Figure 4E, see also Fig-
ure S6C for quantification). Since claspin is an adaptor protein
that facilitates activation of Chk1, a key effector kinase in the
DNA damage response, we also monitored the effect of HBX
19,818 on UV-dependent activation of Chk1, as assessed by
the level of phosphorylation on its Ser317 residue. As expected,
the level of Chk-1 phosphorylation was reduced in HBX 19,818-
treated cells. In these conditions, we also detected a dose-
dependent accumulation of p53 (Figure 4E). These data taken
together indicate that, similar to USP7 knockdown, HBX
19,818 treatment (1) decreases the endogenous level of Phos-
pho-Chk-1, probably as a consequence of lower claspin levels
and (2) increases the level of functionally active p53.
Activity of HBX 19,818 on Cell Proliferation, Apoptosis,
and Cell Cycle
Since USP7 regulates numerous substrates involved in cell
proliferation, we investigated whether HBX 19,818 affected cell
proliferation. We treated exponentially growing HCT116 colon
cancer cells with various concentrations of HBX 19,818 for
72 hr and then assessed proliferation with BrdU incorporation
assays. HBX 19,818 inhibited HCT116 proliferation in a dose-
dependent manner, with an IC50 of 2 mM (Figure 5A). To
evaluate the role of p53 in the cellular response, cell viability
experiments were also performed in three cancer cell lines with
different p53 status: HCT116 (p53wt/wt), DU145 (p53mt/mt), and
HeLa (p53 not regulated by Mdm2). Cell viability was affected
by HBX 19,818 at a similar level whatever the p53 status (Fig-
ure S7), strongly suggesting that p53 seems to play a minor
role in the cellular response.
We next evaluated the ability of the USP7 inhibitor to induce
apoptosis. We treated HCT116 cells with various concentrations
of HBX 19,818, and then assessed the level of apoptosis by as-
saying caspase-3 activity using a fluorescent substrate or by
monitoring poly(ADP-ribose) polymerase (PARP) cleavage.
HBX 19,818 was shown to induce HCT116 apoptosis in a
dose-dependent manner in both assays (Figure 5B). Given the
interaction of USP7 with cell cycle regulators, such as Mel18,
claspin, PTEN, FOXO4, and p53, we analyzed the HCT116 cellChemistry & Biology 19,cycle after HBX 19,818 treatment for 24 hr. Cell cycle analysis
revealed that the G1-phase fractions of cells treated with HBX
19,818, but not those of the HBX 28,364-treated cells (a negative
control), were significantly greater than those of untreated cells
(Figure 5C). Thus, HBX 19,818 treatment, like USP7 knockdown,
disrupts cell cycling and leads to G1 arrest.
DISCUSSION
The USP7/HAUSP deubiquitinating enzyme is an attractive viral
and oncology target (Colland, 2010). USP7/HAUSP is a cysteine
protease, and one of the main problems hindering the develop-
ment of small-molecule inhibitors of cysteine proteases has
been their lack of specificity. However, various DUBs display
different tolerances for different residues in their active-site
clefts, strongly suggesting that deubiquitinating activity of these
different enzymes might be selectively inhibited by small mole-
cules targeting their active sites (Drag et al., 2008). Indeed,
specific inhibitors of the viral PLPro and the human USP14 pro-
teasome-associated DUBs were recently identified (Lee et al.,
2010; Ratia et al., 2008). The chemical approach to USP7 inhibi-
tion we used here led to the identification of small-molecule
compounds able to specifically inhibit USP7 in several different
assays.
We found that theseUSP7 inhibitors did not significantly inhibit
any of the other deubiquitinating enzymes or the less distantly
related cysteine proteases we tested in in vitro enzyme assays
of recombinant proteins (IC50 > 200 mM). Since enzyme behavior
can be more complex in cellular contexts, as illustrated with the
recent native kinase binding profiles of kinase inhibitors (Patri-
celli et al., 2011), we used the HAUbVS competitive probe to
characterize inhibitor interactions with endogenously expressed
deubiquitinating enzymes in a native proteome. This probe was
used previously to discover and characterize novel ubiquitin/
ubiquitin-like proteases and profile active deubiquitinating
enzymes in normal, virus-infected, and malignant cells (Boro-
dovsky et al., 2002; Hemelaar et al., 2004; Ovaa et al., 2004).
In these experiments, this class of inhibitors, represented by
HBX 19,818 and HBX 28,258, inhibited HAUbVS binding to
USP7 with IC50 values of 25–50 mM and exhibited excellent
selectivity compared to the nonspecific DUB inhibitor HBX
41,108. One specific feature of the USP7 structure is character-
ized by the different conformation of the catalytic site between
the apo-enzyme and the enzyme bound to its natural substrate,
ubiquitin (Hu et al., 2002). The marked difference in position
between the catalytic residues with and without ubiquitin,
observed by superimposition of the two available X-ray struc-
tures, is not observed in other pairs of available structures solved
with and without ubiquitin (Sippl et al., 2011). Since HBX 19,818
targets the USP7 catalytic site, its selectivity could be linked to
this specific structural feature of USP7.
We also showed that these HBX compounds hit the USP7
target, as they disrupted HAUbVS competitive labeling of
USP7 in live HCT116 cells. These results demonstrated that
the active site of USP7 could be occupied by a small molecule
inhibitor in living cells. The specificity of this target occupancy
was illustrated by the absence of any off-target activity for
HBX 19,818 across several different endogenous deubiquitinat-
ing enzymes activities detected in HCT116 cells. In cancer cells,467–477, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 473
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Figure 5. Effect of HBX 19,818 on Cell Proliferation, Apoptosis, and Cell Cycle
(A) Treatment for 72 hr with HBX 19,818 decreased HCT116 cell proliferation in a dose-dependent manner (BrdU incorporation).
(B) Caspase activity was assessed in HCT116 cells following HBX 19,818 treatment (10–30 mM) for 6 hr, using the caspase assay described in the Experimental
Procedures. PARP cleavage was detected by western blotting following the treatment of HCT116 cells with HBX 19,818 (10–30 mM) for 6 hr.
(C) HCT116 cells were treated for 24 hr with DMSO, HBX 19,818 (3–10 mM), HBX 28,258 (3–10 mM), or HBX 28,364 (30 mM), and cell cycle profiles were analyzed by
fluorescence-activated cell sorting analysis. Cell cycle analysis is presented as a bar chart showing the percentage of cells in subG1, G1, S, and G2-M.
See also Figure S7.
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Inhibitor of USP7 Deubiquitinating EnzymeUSP7 targeting by HBX 19,818 compromised UV-induced Chk1
phosphorylation and decreased the level of the checkpoint
mediator Claspin; both of which occur in response to USP7
knockdown. This targeting was confirmed by the observation
that HBX 19,818 modulated the endogenous levels of additional
USP7 substrates such as Mdm2 and p53. Regarding Mdm2, we
found that higher levels of the ubiquitinated forms of Mdm2 were
stabilized by HBX 19,818 treatment and led to Mdm2 degrada-
tion, which again resembled USP7 silencing (Sippl et al., 2011).
All these data suggest that the observed effects of HBX 19,818
are likely the result of USP7 targeting. Most attempts to target
Mdm2 have focused on the identification of small molecules,
such as the nutlins, which prevent its interaction with p53 (Vassi-
lev et al., 2004), or on inhibiting its E3 ligase activity (Yang et al.,
2005). We adopted an alternative approach based on the
identification of small-molecule inhibitors of USP7; an ubiqui-474 Chemistry & Biology 19, 467–477, April 20, 2012 ª2012 Elseviertin-specific protease required for Mdm2-dependent p53
destabilization. Using HBX 19,818, we found that disrupting
USP7 reduced HCT116 cell proliferation, induced caspase
activity and PARP cleavage, and arrested HCT116 cancer cells
in G1. However, it remains unclear if the mild decrease in endog-
enous Mdm2 levels observed in response to inhibitor is respon-
sible for upregulation of p53 thus suggesting the involvement of
other mediators of p53 induction. Indeed, whereas Mdm2 is
sufficient to target p53 for degradation, there is good evidence
that it does not function alone. Several proteins, such as
transcription factors and E3 ubiquitin ligases, have been shown
to be involved in the regulation of p53, and an in-depth charac-
terization of USP7 protein partners in this pathway may help to
identify the target effector of USP7 inhibition. In addition,
because we observed a minor role of p53 in the cellular
response, we cannot exclude that USP7 regulates the functionLtd All rights reserved
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that HBX 19,818 has additional off-target, p53-independent
proapoptotic effects.
These compounds were shown to be irreversible inhibitors of
USP7 through nucleophilic attack of its catalytic cysteine, result-
ing in chloride release and covalent binding. Molecular docking
hypotheses based on the structure of the ubiquitin-bound
USP7 core are consistent with such a mechanism. This irrevers-
ible mechanism of action for HBX 19,818 is supported by our
competitive HAUbVS results showing that inhibition of USP7
was sustained in cellular extracts of HBX 19,818-treated
HCT116 cells. Assuming that HBX 19,818 is an irreversible
inhibitor, evaluation of USP7 target occupancy in animal models
could be envisaged, as previously described for irreversible
hydrolase inhibitors (Chang et al., 2011). This would allow the
extent and duration of USP7 target inhibition to be determined
as well as its relationship to antitumor activity, an important
parameter in a drug discovery process. Future experiments
with these covalent inhibitors could also include their use as
powerful tools for defining the binding site for reversible inhibi-
tors on USP7 enzyme molecules and their use as probes by
incorporating a fluorophore into the HBX 19,818 structure to
image USP7 activity in vivo.
There is increasing evidence to suggest that DUB inhibition is
potentially useful for the treatment of viral disease, neurological
disorders and cancer treatment. This study provides proof-of-
principle that specific cell-permeable inhibitors of USP7, a critical
oncology target, can be identified. Further structure-activity
relationships and protein structural studies will be required to
assess the potential for USP7 inhibitors as therapeutics in
cancer. These inhibitors can also be valuable tools for studying
USP7-mediated deubiquitination.
SIGNIFICANCE
Regulated protein turnover is primarily controlled by the
ubiquitin-proteasome system. Ubiquitin-specific proteases
are involved in the deubiquitination of specific target sub-
strates regulating their stability, subcellular localization
and/or activation status. The strong connection of USPs
with cancer phenotypes clearly highlights these proteins
as attractive candidates for cancer drug discovery. The
human USP7 deubiquitinating enzyme appears as such a
strategic target for cancer therapy since it regulates many
proteins involved in the cell cycle, as well as tumor suppres-
sors and oncogenes. One of the most acute challenges in
developing cysteine protease inhibitors with lead-like prop-
erties is selectivity. This could predictably be an issue with
USPs as they constitute the largest family of human cysteine
proteases, gathering more than 60 different members.
Specific inhibitors of the viral PLPro and the human USP14
proteasome-associated deubiquitinating enzymes were
recently identified. In this work we discovered specific and
cell-active inhibitors of the USP7 deubiquitinating enzyme
using biochemical assays and activity-based protein pro-
filing in living systems. The therapeutic potential of inhibiting
USP7was demonstrated by the observation that these inhib-
itors can bind directly and specifically to USP7 andmodulate
the steady-state levels of several USP7 substrates. TheChemistry & Biology 19,current USP7 inhibitors also can be a valuable chemical
tool for studying USP7-mediated deubiquitination.
EXPERIMENTAL PROCEDURES
Protein Production and Purification
Full-length wild-type and catalytic mutant (cysteine 223 replaced by alanine,
C223A) human His-USP7 proteins, as well as full-length wild-type human
His-USP8, were produced in Spodoptera frugiperda cells (Sf9; Invitrogen,
Carlsbad, CA, USA) using the Bac-to-Bac baculovirus system from Invitrogen
in accordance with the manufacturer’s instructions and purified as previously
described (Colland et al., 2009). Recombinant SENP1 (E-700), USP2 (E-506),
USP5 (E-322), USP20 (E-344), UCH-L1 (E-340), and UCH-L3 (E-325) proteins
were provided by Boston Biochem (Cambridge, MA, USA). Cathepsin B and
caspase-3 were provided by Calbiochem (219364; Darmstadt, Germany)
and BD Biosciences (556472; Franklin Lakes, NJ, USA), respectively.
HTS Screening
Deubiquitinating enzyme activity was monitored in a fluorometric assay,
using ubiquitin-AMC (ubiquitin-7-amido-4-methylcoumarin, Boston Biochem,
U-550) as a substrate (Dang et al., 1998). USP7 has been shown to catalyze
Ub-AMC hydrolysis. The AMC released from the C terminus of ubiquitin
displays enhanced fluorescence, which can be monitored with a fluorescence
reader. USP7 inhibitors were identified by screening a proprietary library of
36,000 chemically diverse compounds (Monge et al., 2006) for inhibition of
the enzyme-mediated cleavage of the AMC fluorophore from ubiquitin-AMC.
HTS assays were performed using a Perkin Elmer (Waltham, MA, USA) Janus
automated liquid handler and a 384-well format (Greiner black plates). Both
enzyme and substrate were freshly prepared in USP7 reaction buffer
(50 mM Tris-HCl [pH 7.6], 0.5 mM EDTA, 5 mM DTT, 0.01% Triton X-100,
and 0.05 mg/ml serum albumin) for each run. USP7 (100 pM) were pre-incu-
bated with DMSO (5%) or compounds (10 mM) for 30 min, and the enzymatic
reaction was initiated by adding the UbAMC substrate (300 nM). The reaction
mixture was incubated at room temperature for 1 hr, and the reaction was
stopped by adding acetic acid (100 mM). Fluorescence emission intensity
was measured on a PHERAstar (BMG Labtech, Ortenberg, Germany)
machine, using a coumarin filter set (lex = 360 nm, lem = 460 nm). The Z’ factor,
a standard statistical parameter for HTS assays, was 0.92, indicative of a
robust HTS assay (>0.5; Zhang et al., 1999).
Cysteine Protease Fluorogenic Substrate Activity Assay
The ability of HBX 19,818 and HBX 28,258 to inhibit a panel of deubiquitinating
enzymes, including UCH-L3 (13 pM), USP7 (100 pM), USP8 (1.36 nM), UCH-L1
(2.5 nM), USP5 (10 nM), USP20 (10 nM), and USP2 (500 pM), was tested using
the UbAMC substrate (300 nM). The potential effects of HBX 19,818 and HBX
28,258 were also tested on the enzymatic activities of SENP1 (80 pM),
cathepsin-B (100 pM), and caspase-3 (100 pM) using the SUMO1-AMC
(750 nM), ZRR-AMC (3 mM), and DEVD-AMC (250 nM) substrates, respec-
tively. All enzymes were tested in USP7 reaction buffer (50 mM Tris-HCl [pH
7.6], 0.5 mM EDTA, 5 mM DTT, 0.01% Triton X-100, and 0.05 mg/ml serum
albumin), except for two enzymes, USP8 (same buffer but pH 8.8) and
caspase-3 (100 mM HEPES [pH 7.5], 10% sucrose, and 0.1% CHAPS). All
enzymes were pre-incubated with DMSO or compounds for 30 min at room
temperature, and the enzymatic reaction was initiated by adding the substrate
of interest. The reaction mixture was incubated at room temperature for 1 hr,
and the reaction was stopped by adding acetic acid (100 mM). The reactions
were monitored using the PHERAstar (BMG Labtech).
Mass Spectrometry
Prior to MS experiments, detagged USP7 was buffer exchanged against
50 mM ammonium acetate (pH 7.5). For compound binding analysis by native
MS, protein (5 mM) was incubated overnight at 18C in 10 mM ammonium
acetate (pH 7.5) in the presence of increasing compound concentrations
(5 to 50 mM). Denaturing mass spectra of USP7/HBX 19,818 complex were
obtained after 5-fold dilution of protein/ligand mixtures in 50% acetonitrile/
0.5% formic acid. For a peptide mapping experiment, trypsin-digested
USP7/HBX 19,818 covalent complex was analyzed by reverse-phase liquid467–477, April 20, 2012 ª2012 Elsevier Ltd All rights reserved 475
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peptides were collected after RPLC separation and submitted to high-resolu-
tion MS and MS/MS experiments. Additional details regarding MS experi-
ments are given in the Supplemental Experimental Procedures.
Labeling and Competition for Deubiquitinating Activity
with the HAUbVS Activity-Based Probe
HCT116, as well as HEK293, cells were harvested and lysed on ice with a non-
denaturing buffer containing 50 mM Tris [pH 7.4], 150 mM NaCl, 5 mMMgCl2,
0.5 mM EDTA, 2 mMDTT, 2 mM ATP, 0.5% NP40, and 10% glycerol. Proteins
fromnondenatured cell lysates (50 mg)were treatedwith compounds of interest
for 2 hr at room temperature. The ubiquitin labeling reaction was initiated by
adding HAUbVS (to a final concentration of 1 mM) in labeling buffer (50 mM
Tris [pH 7.6], 5 mM MgCl2; 0.5 mM EDTA, 2 mM DTT, 2 mM ATP and 250 mM
sucrose), and the reaction was allowed to proceed in a final volume of 30 ml
at room temperature for 15 min. To evaluate drug occupancy on USP7 in cells,
living HCT116 cells were also directly treated with HBX 19,818 compound for
6 hr, harvested, and lysed on ice in the nondenaturing buffer described
previously. Samples were incubated at 4C for 1 hr, briefly sonicated, and
clarified. Proteinswere thenquantifiedusingbicinchoninic acid (Sigma-Aldrich,
St. Louis, MO, USA). The ubiquitin labeling reaction was initiated by adding
0.3 mg HAUbVS to 50 mg of proteins from nondenatured cell lysates. The reac-
tion was allowed to proceed at room temperature for 15 min. Samples were
then heated at 100C for 5 min, briefly sonicated, and processed for immuno-
blotting as described in the Western Blot Experiments paragraph.
Cell Culture Analysis
Human embryo kidney HEK293 cells (European Cell Culture Collection) were
maintained in Dulbecco’s modified Eagle’s medium, supplemented with
10% FBS, 2 mM glutamine, 1 mM sodium pyruvate, and 1% nonessential
amino acids. Human colon carcinoma HCT116 cells were maintained in
McCoy’s 5A medium, supplemented with 10% FBS and 3 mM glutamine.
Human osteosarcoma U2OS cells (European Cell Culture Collection) were
maintained in Mc Coys’ 5A medium, supplemented with 10% FBS and
1.6 mM glutamine. Human osteosarcoma SJSA-1 cells (American Type
Culture Collection) were maintained in RPMI 1640 medium, supplemented
with 10%FBS, 2mMglutamine, 10mMHEPES, and 2.4 g/l glucose. All culture
media were supplemented with 100 units/ml penicillin and 0.1 mg/ml strepto-
mycin, and cell lines were cultured at 37C in a humidified atmosphere
containing 5% CO2. Following compound treatment for the indicated time at
the indicated concentrations, cells were always washed once in PBS and
harvested by treatment with trypsin. Cell proliferation, apoptosis, and cell
cycle studies are described in the Supplemental Experimental Procedures.
Western Blot Experiments
Following HBX 19,818 treatment for the indicated time at the indicated
concentrations, cells were washed once in PBS and harvested by treatment
with trypsin. Detached and trypsin-treated cells were pooled and collected
by centrifugation. Cells were then resuspended in lysis buffer (2%SDS supple-
mented in 1X protease inhibitor cocktail; Sigma-Aldrich), heated for 10 min at
100C, and briefly sonicated. Proteins were quantified using bicinchoninic acid
(Sigma-Aldrich) in accordance with the manufacturer’s instructions and
resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). Separated proteins were transferred to a nitrocellulose mem-
brane and probed with antibodies against p53 (DO-1; Santa Cruz; sc-126),
p21 (BD PharMingen; 556430), PARP (Cell Signaling, Danvers, MA, USA;
9542), Mdm2 (SMP14; Santa Cruz; sc-965), HA (BabCO; MMS-101P), USP7
(Calbiochem; DR1014), USP5 (Bethyl Lab; A301-542A), USP10 (Epitomics;
3148-1), CYLD (Santa Cruz; sc-137139), USP8 (Sigma-Aldrich; HPA004869),
UCH-L3 (Cell Signaling; 3525S), caspase-3 (Cell Signaling; 9661), phospho-
S317-Chk1 (Cell Signaling; 2344S), Chk1 (Santa Cruz; sc-8408), Claspin
(Bethyl Lab; A300-266A), stat3 (Cell Signaling; 9132), and actin (Sigma-Aldrich;
A2066). Horseradish peroxidase (HRP)-conjugated anti-mouse (Jackson
Laboratories, Bar Habor, ME, USA; 115-035-003) or HRP-conjugated anti-
rabbit (Cell Signaling; 7074) antibodies were used as secondary antibodies.
Signals were detected by enhanced chemiluminescence (Pierce ECL or
Amersham ECL Advance) in accordance with the reagent manufacturer’s
instructions.476 Chemistry & Biology 19, 467–477, April 20, 2012 ª2012 ElsevierDeubiquitination Assays
HEK293 cells were transfected with the constructs indicated. Forty hours
after transfection, cells were treated for 24 hr with various concentrations of
HBX 19,818 and lysed in urea lysis buffer (0.1 M sodium phosphate [pH 8.0],
10 mM Tris-HCl [pH 8.0], 300 mM NaCl, 8 M urea, 0.1% Triton X-100, and
20 mM imidazole). Ubiquitinated proteins were precipitated from urea lysates,
using Ni-NTA agarose beads (Qiagen, Germantown, MD, USA), essentially as
described previously (van der Horst et al., 2006), and analyzed by western
blotting for the presence of Mdm2. For the in vitro deubiquitination of p53 by
USP7, the purified enzyme (3 nM final concentration) was incubated with
HBX 19,818 at the indicated concentration for 30 min at room temperature
before the addition of purified p53 that had been polyubiquitinated by
Mdm2 (kindly provided by O. Coux). Reactions were incubated for 90 min at
37C and stopped by adding denaturing 1X NuPAGE LDS Sample Buffer
(Invitrogen) and 0.1 M DTT (final concentration). Samples were resolved
by SDS-PAGE, and the separated proteins were then transferred to a nitrocel-
lulose membrane and probed with anti-p53 antibody (DO-1; Santa Cruz;
sc-126).SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.chembiol.2012.02.007.
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